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2. Introduction 
 
2.1 Mast cells are important effector cells in allergic TH2 responses 
The mast cells are central effector and regulatory cells in IgE mediated allergic reactions and Th2-
dominated immune responses (1). Binding of antigens to receptor bound IgE results in release of 
inflammatory mediators such as histamine, leukotriene (LT) C4 and Prostaglandin (PG) D2 (1), in 
addition to a variety of different TH2 cytokines, including IL-4, IL-5, IL-6, IL-10 and IL-13, 
which has been implemented in the pathogenesis of allergic reactions (2, 3, 4, 5). Asthmatic 
airway inflammation has been strongly linked to Th2 lymphocytes and their cytokines, 
particularly IL-4, IL-5 and IL-13, which regulate airway hyper responsiveness, eosinophil 
activation, mucus production and IgE secretion (6).  
Mucosal mast cells lie adjacent to nerves, blood vessels and lymphatics, which highlights 
their pivotal importance in regulating allergic inflammatory processes. In allergic asthma, mast 
cells are predominantly activated by IgE receptor cross linking, and mediators from degranulating 
mast cells are critical to the pathology of the asthmatic lung. Mast cell proteases stimulate tissue 
remodeling, neuropeptide inactivation and enhanced mucus secretion, while histamine stimulates 
smooth muscle cell contraction, vasodilatation and increased venular permeability and further 
mucus secretion (7). 
 
2.2 Mast cells are important in the immune response to bacterial products 
In addition to IgE-mediated allergic reactions, mast cells are important in the immune defense 
against Gram-negative bacteria through release of TNF-α (5, 8, 9) , and can perceive infectious 
agents either by complement-dependent mechanisms or through Toll-like receptors interacting 
with bacterial products (10). Endotoxin, or LPS, is a prominent pathogen-associated molecule 
embedded in the cell wall of Gram-negative bacteria. Mast cells respond to LPS by producing IL-
1β, IL-5, IL-6, IL-13 and TNF-α without degranulation (5, 11-13). 
 
2.3 Complement is important in the development of asthma 
C3a activate mast cells through their G-protein coupled receptor, C3aR, and this lead to a 
mobilization of intracellular calcium and thereby activation of the cell (6, 14, 15). The 
anaphylatoxin Complement C3a fragment and its receptor were recently shown to be important in 
the development of bronchial hyper reactivity, recruitment of airway eosinophils, IL-4 production, 
and IgE responses (13). Moreover, a deletion in the C3a receptor gene, resulting in no C3a 
receptor expression, ameliorated allergen induced bronchial contraction, mucus secretion and 
recruitment of inflammatory cells in a murine asthma model (16). Both mast cells and eosinophils 
express the C3a receptor; and the inability of the allergen induced C3a formation to activate these 
cells, may have inhibited the asthma reactions. Non-IgE dependent mast cell activation may 
actually be very important as IgE-deficient mice still developed antigen-induced airway hyper 
responsiveness (14, 17). IgE-mediated activation of mast cells normally induce secretion of 
preformed proteoglycan bound mediators such as, TNFα, IL-4, 5, 6, 10 and13, histamine, tryptase 
and chymase. In addition to these, new synthesis of arachidonic acid metabolites (leukotriene C4 
(LTC4), leukotriene B4 (LTB4) and prostaglandin D2 (PGD2)) are stimulated. These substances are 
all important cytokines in the pathology of the asthmatic lung (2- 5, 7- 9).  
Human asthmatics generate significant levels of C3a following intra-bronchial allergen 
deposition, but not saline. C3a was shown to be released to the bronchoalveolar lavage fluid 
(BAL) after allergen challenge in asthmatic lungs of 15 patients. The same study reports that the 
eosinophil and neutrophil infiltrate in BAL fluid correlates highly with the amount of C3a present 
(18). This indicates that the innate immune system and complement (C3a in particular) are 
involved in the pathogenesis of asthma.  
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2.4 Human mast cell-1 (HMC-1) 
The HMC-1 cell line was established from a patient with mast cell leukemia in 1987 by Dr. J. H. 
Butterfield  and colleagues (19). HMC-1 has a unique chromosomal 10;16 translocation and bears 
many similarities to immature mast cells. HMC-1 grows in the absence of human plasma or 
leukocyte-conditioned medium, and is relatively stably arrested in a specific differentiation state. 
The cell line contain low levels of histamine, are stained metachromatically by toluidine blue, and 
contain chloroacetate esterase, aminocaproate esterase and tryptase activities. Heparin and 
chondroitin sulfate are found in approximately equal amounts. The cells lack T- and B-
lymphocyte markers but express (similar to normal mast cells) the monocyte/macrophage marker 
CD68 and contain mRNA for the eosinophilic/basophilic-related differentiation marker: the 
Charcot-Leyden crystal. The cell does not, however, express the high affinity IgE receptors (19, 
20).  
 There are two sublines of HMC-1, named HMC-1560 and HMC-1560,816, with different 
phenotypes and designated by the specific mutations in the c-kit proto-oncogene. Both sublines 
have a heterozygous T to G mutation at codon 560 in the juxtamembrane region of the c-kit gene 
causing an amino acid substitution of Gly-560 for Val. However, only HMC-1560,816 cells have the 
V816 mutation found in mast cell neoplasms causing an Asp→Val substitution at the intracellular 
kinase domain. However, c-Kit is constitutively phosphorylated on tyrosine residues in both 
HMC-1 variants. This activation is associated with phosphatidylinositol 3´-kinase (PI 3-kinase) 
without constitutive phosphorylation of Act or extra cellular regulated protein kinase (ERK), 
which are signaling molecules normally activated when SCF bind c-Kit. This leads to the constant 
activation and growth of the mast cell lines. This documentation and characterization of the two 
HMC-1 sublines provides both information on the biological consequences of mutations in Kit 
and recognition of the availability of what in reality are two distinct cultured human mast cell 
lines (20- 23).   
 HMC-1 express mRNA for TNF-α, TGF-β, IL-1β, IL-3, IL-4; IL-8 and a low level of M-
CSF, constitutively. They can also be induced to express several cytokines i.e. IL-1β, IL-3, IL-6, 
GM-CSF, TNF-β and PDGF-A (Platelet derived growth factor-A, which stimulate fibroblast 
proliferation and migration and has been implicated in a number of fibroproliferative disorders). 
Interleukin-4 (IL-4) is a well-characterized mast cells regulator of growth and function. HMC-1 
expresses IL-4 receptor and IL-4 down-regulated IL-1β mRNA and protein expression, but had no 
effect on TNF-α mRNA expression. Increased transcripts for TH2 cytokines are not detected after 
stimulation with IL-4, IL-2, IL-3, IL-6 and IL-8 (24). Thus, human mast cells have the capacity to 
express not only cytokines mediating immune response, but also cytokines affecting other cell 
types, e.g. fibroblasts and endothelial cells, involved in later steps of the inflammatory response 
(25, 26).  
 HMC-1 expresses both the high affinity C3aR1 receptor, and the low affinity C3aR2 
receptor. Both are expressed at a high level (27). C3a function as a chemotaxin to HMC-1. This 
anaphylatoxin-mediated recruitment of mast cells might play an important role in hypersensitivity 
and inflammatory processes (28). Data also suggest that the HMC-1 high affinity C3aR receptor 
respond to C3a only, and not to C3a(desArg) (15).  
 HMC-1 express 5-lipoxygenase (5-LO) activity and produce 5-hydroxyeicosatetraenoic 
acid (5-HETE) as the major metabolite (29). Following this HMC-1 (and cord blood derived mast 
cells) is equipped with two enzymes that can catalyze the committed step in the biosynthesis of 
cysteinyl-leukotrienes (cys-LTs). The expression of the cognate receptor CysLT1 suggests 
moreover, that these lipid mediators may be involved in autocrine signaling pathways regulating 
mast cell functions. These enzymes synthesize leukotriene C4  (LTC4). Both are GSH transferases 
termed LTC4 synthase (LTC4S, typically expressed in certain bone marrow-derived cells such as 
eosinophils and mast cells) and microsomal GSH transferase type 2 (mGST-II). The Cys-LTs 
LTC4 and 11-trans-LTC4 are increased in allergic inflammation and induce smooth muscle 
contracting, mucus secretion and was previously known as the slow reacting substance of 
anaphylataxis (30). HMC-1 cells contain the enzyme activities required to metabolize LTC4 
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further into LTD4 and later into LTE4. The prostanoid profile includes PGE2, PGF2α and PGD2, 
but not prostacyclin. The cells are also able to produce substantial amounts of thromboxane (TX) 
A2, quantities exceeding those of LTC4, suggesting that mast cells may be an important source of 
thromboxane and pointing to a possible role of these cells in hemostasis and thrombosis (29).  
 
2.5 Cord blood derived mast cells (cbd-MC) 
The cord blood-derived human mast cells were developed by Christine Dahl et al (31). Human 
cord blood progenitors were purified with anti-CD133 antibody, and then cultured in a serum-free 
medium supplemented with SCF and IL-6 for 8 weeks (32-37). The cells were thereafter cultured 
for 4 weeks in media supplemented with 10% fetal calf serum (FCS). The addition of FCS 
increased histamine and FcεRI expression, and released more histamine after anti-IgE stimulation 
than those that had grown in serum containing media only (31). All cultured human MCs produce 
chymase in a clonally regulated but cytokine-independent manner (38) and express tryptase in 
their cytoplasmic granules (39).  
Cbd-MC constitutively express the immune modulating and fibroblast activating cytokine 
transforming growth factor β1 (TFG-β1) and release it continually, with no increase after IgE-
receptor cross-linking. This in contrast to platelet-derived growth factor-β (PDGF-β) and basic 
fibroblast growth factor (bFGF) which is up-regulated after IgE-receptor cross-linking. Activated 
human mast cells produce fibrinogenic factors such as PAI-1, suggesting an important role for 
mast cell cytokines in fibrosis (40, 41).  
 Cbd-MC cells release histamine, TNF-α, sulfidoleukotrienes (LTs) and prostaglandin D2 
(PGD2) after IgE receptor cross-linking (34, 42, 43). Preincubation with SCF, IL-4, IL-5 or IL-6 
for 24 hours during sensitization with IgE enhances FcεRI -receptor mediated histamine release, 
whereas IL-3 showed a negligible effect (44). IL-4 may also induce IL-5 production in cbd-MC 
(45).   
 Cbd-MC produce and release IL-13 after FcεRI -receptor and calsium ionophore A23187 
stimulation in the presence of SCF only (46). Whereas the TH2 cytokine IL-4 stimulate the IgE-
mediated mast cell production of macrophage inflammatory protein 1α (MIP-1α), IL-8 and 
granulocyte macrophage-colony stimulating factor (GM-CSF), the TH1 cytokine IFN-γ 
reciprocally inhibits the production (47). IFN-γ may even stimulate histamine release from cbd-
MC (48). Thus, both TH2 and TH1 cytokines may influence human mast cell functions in allergic 
reactions. 
 Peptidoglycan (PGN) from Staphylococcus aureus induce cbd-MCs to release TNF-α, IL-
5, IL-10 and IL-13 through interactions with Toll-like receptor 2 (TLR2), while 
lipopolysaccharide (LPS) from Escherichia coli invokes the same response through TLR4. The 
TNF-α release induced by LPS required priming of cbd-MC by IL-4 and the presence of serum 
components, in particular CD14. Stimulation with PGN, but not LPS, induce release of histamine. 
Activation of either TLR2 or TLR4 pathway may lead to a pro-TH2 immune response. These 
findings show that human MC differentially responds towards bacterial components with 
production of specific cytokines, and that their response depends on TLR pathways (5). 
 
2.6 Aims  of the study 
Our objective was to examine gene regulation following C3a and LPS stimulation of human mast 
cells. HMC-1 and cbd-MC cells were used in the studies to simulate normal human mast cells. We 
used microarray, which is a powerful tool to investigate differential gene expression of thousands 
of genes of a cell type, tissue, or organism. Microarray was used to detect changes in gene 
expression upon stimulation, then we used PCR analysis to confirm and differentiate these 
findings. The fact that mast cells respond to complement and bacterial products may indicate an 
important role in modulating other inflammatory processes, e.g. periodontal disease and muco-
cutaneous contact stomatitis.  
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3. Materials and methods 
 
3.1 Antibodies 
Recombinant human C3a was a gift from Dr. Jörg Zwirner at the University of Göttingen. 
Calsium Ionophore III A23187 ( Ionophore), Phorbol 12-Myristate 13-Acetate (PMA) and 
Lipopolysaccharide from E.coli 0111:B4 (LPS) were all obtained from Sigma-Aldrich (St. Louis, 
MO, US). Recombinant human Interleukin-4 (IL-4) and recombinant human Interferon-γ (IFN-γ) 
were both purchased from R&D systems (Minneapolis, MN, US). For the flow cytometric 
analysis C-kit antibody CD-117 1/2000 suspension (DAKO a/s, Denmark), C3aR from clone 
76/415 mouse-IgG1 1/2000 suspension (kindly provided by Dr. Zwirner, Göttingen), 
Phytoerethrin (PE) goat anti-mouse IgG1 RPE 1/200 suspension (Southern Biotechnologies 
Associated Inc, Birmingham, AL, US) and FITC goat anti-mouse IgG1(γ1) (Molecular Probes, 
Oregon, US) were used. 
 
3.2 Cells and culture conditions 
The human mast cell line, HMC-1 (kindly provided by J. H. Butterfield; 19), were grown in 
Iscove`s medium (PAA Laboratories GmbH, Austria) supplemented with 10% iron-supplemented 
bovine calf serum (Sigma), thioglycerol (Sigma) and penicillin/ streptomycin (GIBCO, Invitrogen 
corp.) at concentrations ranging from 2,5x105 to 1x106 cells pr ml. at 37°C in a humidified 
atmosphere with 5% CO2 and passed twice a week. The cord blood derived mast cells, cbd-MC 
(kindly provided by C. Dahl; 31) were cultured from 105 CD133+ cells progenitor cells using a 
serum-free condition for weeks 0 through 8. After 8 weeks of culture >8x106 mast cells were 
always generated. This was then followed by a serum supplemented maturation phase for 4 
weeks. This yielded a mast cell that had an increased amount of histamine pr cell (3.8 pg/cell), 
and expressed more FcεRIα. These were cultured in the same medium and conditions as the 
HMC-1 cells. 
 
 
3.3  Cell culture for microarray analysis  
 
3.3.1 HMC-1 stimulated with C3a or Ionophore. 
The aim of the study was to examine gene expression in HMC-1 following C3a stimulation. To 
obtain enough total RNA for microarray hybridization we needed between 40 and 80µg total 
RNA. There are approximately 5µg total RNA in106 HMC-1 cells. The cells were therefore grown 
at large scales using 20x106 cells for each experiment and time point. For the microarray 
experiment 12x20ml cultures of HMC-1 cells were set up at a concentration of 1x106 cells pr ml 
(20ml flasks; Nalge NUNC int., Denmark) and incubated at 37°C in a humidified atmosphere 
with 5% CO2. 20x106 unstimulated HMC-1 cells were harvested at each time point (0, 2, 4, 8 and 
16 hours as negative controls). 20x106 Ionophore stimulated HMC-1 cells were harvested after 4 
hours as a positive control, and 4x HMC-1 cells (80x106) stimulated with rhC3a (100ng/ml) and 
20X106 cells were harvested at each time points (2, 4, 8 and 16 hours). When harvested, the 
medium were transferred into 50ml falcon tubes (Nalge NUNC int., Denmark) and centrifuged at 
800 rpm for 8 minutes at 4°C during which time the cells remaining adherent in the 20ml flask 
were lysed with 4ml TRI  Reagent (Molecular Research Center, Cincinnati, OH, US) and placed 
on ice. The supernatant was then removed from the falcon tube and the TRI Reagent moved 
from the 20ml flask to the tube to lyse the cell pellet; the solution was then stored at -70°C prior 
to use.   
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3.3.2 HMC-1 stimulated with C3a, PMA, Ionophore and LPS 
The aim of the study was examine gene expression in HMC-1 following C3a, PMA, Ionophore 
and LPS stimulation. 16x20ml cultures of HMC-1 cells (320 x106 cells) were set up at a 
concentration of 1x106 cells pr ml (20ml flasks; Nalge NUNC int., Denmark) and incubated at 
37°C in a humidified atmosphere with 5% CO2. Unstimulated HMC-1 cells (80x106) were 
harvested at each time point (2 and 8 hours) as negative controls. 2x20x106 HMC-1 cells were 
stimulated with both PMA (50ng/ml) and Ionophore (10-6M) and harvested after 2 and 8 hours as 
positive controls. HMC-1 cells (20x106 cells at each experiment/time point) were stimulated with 
either rhC3a (500ng/ml), LPS (2 µg /ml) or a combination of LPS (2 µg /ml) and rhC3a (500 
ng/ml) and harvested after 2 and 8 hours. When harvested, the medium was transferred to a 50ml 
falcon tubes (Nalge NUNC int., Denmark) and centrifuged at 800 rpm for 8 minutes at 4°C 
during. The remaining adherent cells in the 20ml flask was then lysed with 4ml TRI Reagent 
and placed on ice. The supernatant was then removed from the falcon tube and the TRI Reagent 
moved over from the 20ml flask to the tube to lyse the cell pellet there; the solution was then 
stored at -70°C prior to use 
 
3.4  Cell culture for CQ-RT-PCR analysis  
 
3.4.1 HMC-1 stimulated with C3a or Ionophore 
The aim of the study was to examine mRNA expression in HMC-1 following C3a stimulation. 
Stimulation with ionophore induce calcium influx mimicking IgE-receptor cross linking and 
served as a positive control for cell activation. For the cq-RT-PCR experiment 16x1ml cultures of 
HMC-1 cells were set up at a concentration of 1x106 cells pr ml (24 well trays; Nalge NUNC int., 
Denmark) and incubated at 37°C in a humidified atmosphere with 5% CO2. Of these, 4x106 
HMC-1 cells were harvested at time 0. HMC-1 cells (12x106 ) were stimulated with either 
recombinant C3a (100 ng/ml) or Ionophore (1x10-6M), and harvested after 2, 4, 8, 12, 16 and 24 
hours. The cells were centrifuged at 800 rpm for 5 minutes at 4°C, and the cell pellet was lysed 
with TRI Reagent (200µl pr well) and stored at -70°C prior to use. 
 
3.4.2 HMC-1 and cbd-MC stimulated with C3a, PMA, Ionophore and LPS 
The aim of the study was to examine the mRNA expression in mast cells following stimulation 
with C3a, PMA, Ionophore and LPS.  For the cq-RT-PCR experiment 11x2ml cultures of HMC-1 
(5x105 cells pr ml) cells and cbd-MC (5x105 cells pr ml) were set up in parallel (24 well trays; 
Nalge NUNC int., Denmark) and incubated at 37°C in a humidified atmosphere with 5% CO2. 
2x106 HMC-1 cells and cbd-MC cells were harvested at time 2 and 4 as negative controls, 3x106 
HMC-1 cells and cbd-MC cells stimulated with Ionophore (10-6M) and PMA (50 ng/ml) were 
harvested at time 2, 4 and 8 hours as positive controls, and 6x106 HMC-1 cells and cbd-MC cells 
stimulated with either rhC3a (500ng/ml) or rhC3a (500ng/ml) and LPS (2 µg/ml) and harvested 
after 2, 4 and 8 hours. The cells were centrifuged at 800 rpm/min for 8 minutes at 4°C, and the 
cell pellet was lysed with 200µl TRI Reagent pr well and stored at -70°C prior to use. 
 
3.5 C3aR expression examined by flow cytometry 
 
3.5.1 C3a-induced C3aR internalization in HMC-1 cells 
This experiment was conducted to examine the levels of receptor expression on the cells and to 
examine whether C3a stimulation would induce C3a-receptor internalization. Three times 1,5x106 
(in a 24 well tray; Nalge NUNC int., Denmark) HMC-1 cells (1x106 cells/ml) were incubated at 
37°C in a humidified atmosphere with 5% CO2 with rhC3a at various concentrations (0 ng/ml, 
100 ng/ml and 1000ng/ml) for 20 hours; then harvested on ice and labeled for flow cytometri. 
Cells (5x104) were incubated (30 min on a gyrating board) on ice with either mAb to c-Kit (clone 
104D2, mouse IgG1, cons. 1/2000; DAKO, Denmark), or mAb to C3aR (clone 76/415, mouse 
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IgG1, cons. 1/2000), or BSA, in a 96 well tray (Greiner). The cells were then washed with 100µl 
washing buffer (PBS+1,5%BSA+azid) and centrifuged at 275G for 5 minutes at 4°C and then 
washed again with 200µl of buffer. The cell pellet was then resuspended in 50µl buffer before 
adding a combination of FITC-labeled goat anti mouse IgG1 (1:200, Southern Biotecnology,  CA, 
US) and phytoerythrin (PE) –labeled goat anti mouse IgG1 (Southern biotechnology) for 30 min 
on ice. The cells were then resuspended in 200µl buffer after they had been washed for 5 minutes 
in 100µl buffer and centrifuged as described above. The cells were assessed in Becton/Dickinson 
FACSCalibur flow cytometer (Becton/Dickinson, Indianapolis, IN, US) using the Cell Quest 
Software (Becton/Dickinson). 
 
3.5.2 C3aR expression in HMC-1 and cbd-MC after IL-4 or IFN-γ stimulation 
The aim of the study was to examine if pre-stimulation with IL-4 or IFN-γ influence the C3a 
receptor expression on mast cells. Three times 1x106 (in a 24 well tray; Nalge NUNC int., 
Denmark) HMC-1 cells and cbd-MC (5x105 cells/experiment) were incubated at 37°C in a 
humidified atmosphere with 5% CO2 with either IL-4 (100ng/ml),  IFNγ (15ng/ml) or nothing for 
24 hrs. The cells were then harvested and prepared for flow cytometry as described above.  
 
3.6 Isolation of RNA, cDNA synthesis and CQ-RT-PCR analysis 
 
3.6.1 Homogenization and Phase separation 
The cells were lysed in 1.0ml TRI Reagent per 5×106 cells by repetitive pipetting and stored for 
5 minutes at room temperature to permit the complete dissociation of nucleoprotein complexes. 
Next, chloroform (0.2ml/ml TRI Reagent) was added and the tube shaken vigorously for 15 
seconds. The resulting mixture was stored at room temperature for 10 minutes and centrifuged at 
12,000g for 10 minutes at 4ºC. The mixture then separated into a lower protein containing phenol-
chloroform phase, a DNA-containing interphase and the RNA-containing colorless upper aqueous 
phase. The Phase lock gelTMHeavy 0.5ml tubes (Eppendorf, Mansfield, TX, US) were used to 
facilitate phase separation when working with small volumes (less than 1×106 cells).  
 
3.6.2 RNA precipitation, washing and solubilization 
The aqueous phase was transferred to a fresh tube and added isopropanol for precipitation using 
0.5 ml of isopropanol per 1 ml of TRI Reagent initially. After mixing, the samples were stored 
in room temperature for 5 minutes followed by centrifugation at 12,000G for 8 minutes at 4º C. 
The RNA precipitate would then form a gel-like or white pellet at the bottom of the tube. The 
supernatant was then removed and the pellet was washed with 75% ethanol and centrifuged at 
12,000G for 5 minutes at 4º C. This step was repeated using at least 1ml of 75 ethanol per 1ml 
TRI Reagent. The ethanol was removed and the pellet air-dried for 2-5 minutes. The pellet was 
then dissolved by adding 50µl DEPC- H2O containing 40u of RNasin® (Promega, Madison, 
WI,US) per 1µl. Samples were then quantified and checked for contamination by looking at the 
260/280 nm ratio. RNA aliquots were diluted with distilled water and spectrophotometry (Perkin 
Elmer MRA2000, Rochester, NY, US) were performed using a distilled water-RNasin® mix for 
calibration. 
 
3.6.3 Reverse transcription  
Reverse transcription (RT) was carried out on 50µl mixtures in 200µl PCR tubes (Perkin Elmer). 
The mixtures contained 0.5µg total RNA based on the spectrophotometric quantization, 2.5µl 
Oligo dt, 10µl of M-MLV-RT buffer (Promega), 5µl DTT (100mM), 1µl dNTP, 1,6µl of RNase 
inhibitor (RNA guard®, Promega) and 2µl of the reverse transcription enzyme M-MLV-RT 
(Promega). Finally DEPC H2O was added to the total reaction volume of 50µl. After 60 min. at 
42ºC the reaction was terminated by heating for 10 min. at 81ºC, followed by immersion on ice.  
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3.6.4 PCR amplification 
PCR reactions were carried out on 25µl mixtures in strips of  200µl MicroAmp® (Perkin Elmer) 
reaction tubes plugged with MicroAmp®Caps (Perkin Elmer). The mixtures contained cDNA, 
2.5µl 10× PCR buffer, 62.5µM dNTP, and 1 unit of TAQ polymerase (In house made 
recombinant TAQ polymerase) and the following primers (100ng of each):  
 
Table.1 Sequence of the PCR-primers used for amplification  
PRIMER SENSE 5` ANTISENSE 5` 
β-actin GGGTCAGAAGGATTCCTATG GGTCTCAAACATGATCTGGG 
IL-1β GGATATGGAGCAAACAAGTGG ATGTACCAGTTGGGGAACTG 
IL-5 CTTGGCACTGCTTTCTACTC GCAGGTAGTCTAGGAATTGG 
IL-10 AAATTTGGTTCTAGGCCGGG GAGTACAGGGGCATGATATC 
IL-13  GAGTGTGTTTGGTCACCGTTG TACTCGTTGGCTGAGAGCTG 
TNF-α ACAAGCCTGTAGCCCATGTT AAAGTAGACCTGCCCAGACT 
C3aR CAGACGGGACTCGTGGAGAC GACAATGATGGAGGGGATGAG 
PGD2S CACAGATTTGGCTGGAAAC CAGAGTTACCAATAAGCCATTC 
COX2 ATTGTCATACGACTTGCAGTGAG TTTACCTTTGACACCCAAG 
 
The mixtures were set up in a sterile environment on ice, followed by centrifugation at 3500rpm 
at 4ºC to prevent air bubbles and ensure complete mixing of the reagents. 
Amplification (40 cycles) was performed on a GeneAmp®PCR System 9700 (PE Applied 
Biosystems, Rochester, NY, US) starting at 94ºC for 3 min, then 40 cycles with 20 sec at 94ºC , 
30 sec at 57ºC and 45 sec at 72ºC, ending at 72ºC for 4 min before cooling down to 4ºC.      
 
3.6.5 Competitive PCR using an internal reference template 
To do a quantitative analysis of our samples we used the competitive PCR method. (TaKaRa 
Biomedicals, Shiga, Japan). The principle of competitive PCR is to ad a known amount of a DNA 
fragment (competitor) to the sample. This competitor must contain sequences for the same 
primers used to amplify the target (our sample).When the target cDNA and the competitor (C) are 
amplified together; both templates will compete for the same set of primers. Because of this 
competition, the ratio of the amounts of the two amplified products reflects the ratio of the 
amounts of the target cDNA and competitor. Since the initial amount of competitor is known, the 
amount of the target cDNA can be estimated according to the target/C ratio  
(Figure1 – 3) 
 
 
 
 
 
  
  
cDNA     C 
PCR 
Figure 1. 
Equal amount of sample cDNA (yellow) is added together with increasing amount of 
the control (C) template (rose). The templates will compete during PCR reaction 
making it possible to estimate the amount of sample cDNA after gel electrophoresis.  
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We used the human β-actin gene as an internal reference template. This housekeeping gene is 
expressed at a constant level in most human cells and tissues and can therefore be used with any 
kind of sample derived from human cell lines (49). 
As competitor we used a Plasmid, PQB2, synthesized by Pascal Legouux et al. (49). This is a 
heterologous competitor (different nucleotide sequence from the target cDNA except for the 
sequences of the primer annealing sites).PQB2 is an ideal competitor because it will be amplified 
by the same primers as our sample cDNA, the amplified product is distinguishable from the 
sample (different amplification length allows the two products to be separated by gel 
electrophoresis) and the competitor is purified and obtained at a known concentration.  
 
3.6.7 Gel electrophoresis, scanning and quantization 
To visualize the competitive PCR results 10µl of each PCR mixture was separated on a 2% 
agarose-gel (Amesco®) in the presence of Ethidium Bromide (0,1%). 
2µl of loading buffer (in house made) were added to the total volume (25µl) of each PCR mixture 
before separation. After a period of approximately 1 hour at 60V a good separation of the 
amplified products was achieved. (fig. 3) 
 
 
PCR products separated on 2% agarose gel 
Wild Type cDNA
Competitor 
250 
350 
0 1 10 100 10 
Figure 2. 
The size of the PCR product depend on the template being used. The sample contain same amount of 
cDNA for the given sequence when its short PCR product matches the longer competitor template (rose). 
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200       1000         5000       25000
350bp
250bp
Plasmid
Product
1 534     24 728    83 457    128 236  
46 640    34 170    27 273    9 089      
 
Figure 3.  
Different amount of the control plasmids (200, 1000, 5000 or 25000) have been added to a fixed amount of samples 
cDNA. The PCR produce a 350 bp product from the plasmid compared to the 250bp product from the samples wild 
type b-actin. The differences in band size are visualized by gel electrophoresis and the band intensities are 
quantified by the use of TortalLab tm from phoretix (nonlinear Dynamics LtD). The bands pixelvolums are 
indicated at the bottom. The sample contain equal amount of b-actin when band intensities equal.    
 
 
Quantitative PCR was performed using 5µl of 1/50 diluted sample cDNA, and 5µl of the 
competitor at concentrations ranging from 40-5000 PQB2 per 1µl. PCR reactions were carried out 
on a total volume of 25µl as described above. A multiwavelenght fluoroimager, capable of optical 
density and fluorescence measurements (ProXPRESS™ProFinder by PerkinElmer), made the 
competitive PCR results available for computerized quantization. Using the built-in image 
analyzing software, taking into account background noise, a graph was plotted of log(T /C) 
against the initial amount of competitor ( T = amount of amplified target  cDNA, C = amount of 
amplified competitor).  
The amount of competitor corresponding to log(T/C)=0  will then correspond to the amount of  β-
actin in our sample (fig.4)  
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Figure 4a: A graph was plotted of log(T/C) against the initial amount of competitor ( T = amount of amplified 
target  cDNA, C = amount of amplified competitor). The amount of competitor corresponding to log(T:C)=0  
corresponds to the amount of  β-actin in sample 
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Based on results obtained from the competitive PCR described above, correction of RNA amount 
among the samples was performed. Samples were diluted to 103β-actin per 1µl. Using 10µl 
sample cDNA for the following PCR analyzes (104 copies of β-actin in each PCR mixture) we 
were able to compare the amount of amplified products from different samples, and relate the 
results to the expression of the housekeeping gene β-actin.   
 
 
 
    
 
Fig. 4b: Contaminated DNA or degraded RNA can potentially give false RNA amounts using optical density 
(OD) measurements. Following competitive PCR samples could be corrected allowing direct comparison of 
PCR results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14
3.7 Microarray analysis 
 
3.7.1 RNA Isolation, Homogenization, 
Phase separation and washing 
 
The cells were lysed in TRI-Reagent, using 
4 ml TRI-Reagent per 20×106 cells. 
800 µl chloroform was added to the 
homogenate, shaken for 15 seconds and 
stored at room temperature for 10 minutes. 
Next, this was centrifuged at 1500g for 10 
minutes at 20ºC. The aqueous phase was 
transferred to a new tube which was 
centrifuged at 1500g for 3 minutes at 20ºC. 
2,4 ml 70% ethanol was added to 2,4 ml of 
the aqueous phase. 4 ml of this was applied 
to RNeasy midi column (Qiagen) and 
centrifuged at max speed for 5 minutes at 
20ºC. The rest of ethanol/aqueous phase was 
applied to the column and centrifuged at max 
speed for 2 minutes at 20ºC. The RNA 
adsorbed to a membrane in the column, and 
the elute thrown.  
 
RNA wash 
2,5 ml RPE was added to the column and 
centrifuged at max speed for 2 minutes. 
Then, 2,5 ml RPE was added again and 
centrifuged at max speed for 6 minutes. 
Next, the column was transferred to a new 
tube, 150 µl RNase-free H2O added, and 
stored at room temperature for 1 minute. The 
tube was centrifuged at max speed for 3 
minutes. The elute was transferred to an 
Eppendorf tube (elute 1). Another 150 µl 
RNase-free H2O was added to the column 
and stored at room temperature for 1 minute 
before centrifuging at max speed for 4 
minutes. The elute was transferred to a new 
Eppendorf tube (elute 2). Elute 1 and elute 2 
were then mixed and frozen. In the 
experiment of effect of C3a, PMA, 
Ionophore and LPS on gene expression in 
HMC-1, an additional precipitation was 
executed. To the elute, 1/10 volume 8M LiCl 
was added and put on ice for 2 hours. Next, 
it was centrifuged at 13000 rpm for 15 
minutes at 4ºC. Washing with 70% ethanol 
and centrifuged at 13000 rpm for 5 minutes 
at 4ºC. The RNA precipitant forms a pellet at 
the bottom of the tubes. They were air dried 
for 3 minutes before dissolved in DEPC-H2O 
and frozen at -70°C. 
. 
 
 
 
 
Figure 5. Total mRNA isolation 
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3.7.2 Labeling by reverse transcription and hybridization 
 
Probe from total RNA 
4 µl 5×first strand buffer, 1 µl oligo dT primer (2 µg/µl dT21V), 2 µl lowT dNTP (5 mM A, C, 
GTP, 2 mM dTTP), 2 µl Cy3-dUTP 1 mM (Amersham, Buckinghamshire, England) (test sample), 
2 µl 100 mM DTT, 60 µg total RNA (test sample) and H2O up to 19 µl were mixed in tubes. The 
same was done with the control sample, except Cy3-dUTP 1 mM was exchanged with Cy5-dUTP 
(Amersham). Test samples and control samples from 2 hours and 8 hours were used. 
The total RNA was concentrated by centrifuging under vacuum to concentration. 
The tubes were well mixed and heated to 65ºC for 5 minutes and then cooled down to 42ºC for 2-
3 minutes. 1 µl SuperscriptІІ (200u/µl Invitrogen) and 1 µl RNasin (Promega) were added to each 
tube and incubated at 42ºC for 30 minutes. Then 1 µl SuperscriptΙΙ was added and incubated at 
42ºC for 40 minutes. At the end of the incubation 2,5 µl 0,5M EDTA was added and incubated at 
65ºC for 1 minute. 5 µl NaOH was added and incubated at 65ºC for 15 minutes to hydrolyze 
RNA. Then 12,5 µl 1M tris was added immediately to neutralize the pH. The volume was brought 
to 70 µl by adding 35 µl TE-buffer. 
Bio-Gel P-6 columns (Bio-Rad, Hemel Hempstead, UK) were prepared by re-suspending 
the gel and remove air bubbles, the tips were cut off, the caps opened and the fluid was allowed to 
be filtered through for 2 minutes and finally centrifuged at 3200 rpm for 2 minutes. 
The samples were transferred to the Bio-Gel P-6 columns and centrifuged at 3200 rpm for 4 
minutes. Then the correlating test sample and control sample were mixed, 200 µl TE-buffer added 
and transferred to microcon 100 (Millipore, Billerica, MA, US). This was centrifuged at 2300 rpm 
to ~20 µl. 400 µl TE-buffer and 10 µl cot DNA (1mg/ml Invitrogen) was added and centrifuged at 
2300 rpm to <20 µl. Next, the columns were turned over in new tubes and centrifuged at 2300 
rpm for 3 minutes. 
 
3.7.3 Hybridization 
DEPC-H2O was added to the samples to a total volume of 24,75 µl. Then 50×Denhardt`s solution 
(SIGMA) 1,5 µl, Yeast tRNA (SIGMA) 1,5 µl, Poly dA (0,1 u/µl Amersham) 2,25 µl and 
20×SSC 3,9 µl were added. This was incubated at 99ºC for 2 minutes. 0,9 µl 10% SDS (sterile-
filtrated) was added and mixed. Next, it was centrifuged. The samples were applied gently against 
the edge of the lifterslips. Hybridization in 50 ml falcon tubes with two pieces of lens paper 
moisturized with 500 µl 2,3×SSC at 65ºC over night. 
Washing: The lifterslips were loosened by holding the slides upside down in 0,5×SSC and 0,01% 
SDS. They were washed on a shaking table in coplin jar covered with aluminum foil. Washing for 
15 minutes in 0,5×SSC and 0,01% SDS, 15 minutes in 0,06×SSC and 0,01% SDS and 15 minutes 
in 0,06×SSC. The slides were dried by centrifuging in falcon tubes at 2800 rpm for 2 minutes. 
 
3.7.4 Computer analysis of Microarray-slides 
The array-slides were scanned using either the GeneTAC UC4 Microarray Analyzer (Genomic 
Solutions, Ann Arbor, MI, US) or the ScanArray®Express Microarray Scanner. The lasers were 
set to a level in which the slides were scanned just below saturation for both Cy3 and Cy5. The 
analyzing tool used for gene identification was GeneTAC Integrator 3.3. Further analysis was 
done by using Spotfire® Decisionsite™.  
QuantArray® Microarray Analysis Software and Microsoft Access were also used for gene 
identification and analysis. 
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Spotfire®Decisionsite™
 
A B
C D
Figure 6.: A  shows the GeneTAC UC-4 scanner used for the first scans. Later, the ScanArray® Express (B) was 
used. C shows part of the scanned microarray, which was analyzed using  Spotfire® Decisionsite™ (D) software.
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4. Results 
 
4.1 C3a and C3a/LPS stimulation of HMC-1 cells 
A B C D 
BIRC3 baculoviral IAP repeat-containing 3 35 602 17 
DEAF1 deformed epidermal autoregulatory factor 1 (Drosophila) 56 561 10 
GEM GTP-binding protein overexpressed in skeletal muscle 26 256 10 
SEMA5A 42 414 10 
Interleukin 1- beta 43 333 8 
MAOA monoamine oxidase A 268 1286 5 
Mannosidase- alpha type II 52 249 5 
NGB GTP-binding protein 50 240 5 
TRAF1 TNF receptor-associated factor 1 144 664 5 
TCF12 transcription factor 12 (HTF4- helix-loop-helix transcription factors 4) 90 414 5 
Homo sapiens protein kinase C-alpha mRNA- partial 3' UTR 45 201 4 
PAI-I 97 417 4 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor- alpha 123 508 4 
BIRC3 baculoviral IAP repeat-containing 3 55 211 4 
Homo sapiens- clone MGC:5618- mRNA- complete cds 169 620 4 
MAN2A1 mannosidase- alpha- class 2A- member 1 143 517 4 
Thrombospondin 1 101 357 4 
ESTs- Moderately similar to unknown [H.sapiens] 152 536 4 
CREM 124 418 3 
IL1B interleukin 1- beta 144 479 3 
PRCC papillary renal cell carcinoma 142 446 3 
FLJ13164 hypothetical protein FLJ13164 64 201 3 
FLJ21016 hypothetical protein FLJ21016 80 249 3 
GTF2F1 general transcription factor IIF- polypeptide 1 66 205 3 
Small inducible cytokine A4 395 1212 3 
Homo sapiens cDNA: FLJ22380 fis- clone HRC07453 73 219 3 
SCYA7 small inducible cytokine A7 (monocyte chemotactic protein 3) 88 265 3 
DDX5 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase- 68kD) 329 982 3 
SCYA4 small inducible cytokine A4 (homologous to mouse Mip-1b) 613 1820 3 
STATI2 STAT induced STAT inhibitor-2 112 333 3 
FLJ20037 hypothetical protein FLJ20037 68 201 3 
CCNA2 cyclin A2 75 221 3 
GBE1 glucan (1-4-alpha-)- branching enzyme 1  118 338 3 
IFI16 interferon- gamma-inducible protein 16 162 463 3 
UBE3A ubiquitin protein ligase E3A  247 706 3 
PDCD2 programmed cell death 2 85 242 3 
KIAA0332 KIAA0332 protein 108 303 3 
FLJ13195 hypothetical protein FLJ13195 similar to stromal antigen 3 90 251 3 
BIRC2 baculoviral IAP repeat-containing 2 154 429 3 
Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) 243 672 3 
 
Table 2.  Results from microarray analysis following C3a/LPS stimulation.  Selection of the most up-
regulated genes.  A: gene name, B: Ch1 (int-backgr), C: Ch2 (int-backgr), D: C/D. The numbers (in B 
and C) represents spot intensities after background subtraction.  
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4.2 C3a/LPS stimulation modifies cytokine mRNA expression in HMC-1 
and cbd-MC 
To examine LPS/C3a-induced cytokine production from mast cells more extensively, HMC-1 
and cbd-MC were stimulated with C3a, a combination of C3a/LPS, and a combination of 
PMA/Ionophore. Total RNA was isolated, and microarray and PCR analysis were performed. 
IL-1β was up-regulated in both cbd-MC and HMC-1 after stimulation with LPS/C3a. (fig.7-
8), TNF-α seemed to be expressed in both cell types, but our studies has failed to prove up-
regulation after stimulation with LPS. IL-5 was only up-regulated in cbd-MC after 
stimulation with C3a and LPS/C3a. IL-10 was expressed in both cbd-MC and HMC-1, and 
was more strongly expressed in cbd-MC. IL-13 seemed to be up-regulated in both HMC-1 
and cbd-MC after stimulation with LPS, and grossly up-regulated after stimulation with 
PMA/Ionophore. PGD2-synthetase was constitutively expressed in both cell types, and was 
not regulated by C3a, LPS or PMA/Ionophore stimulation. Only Cbd-MC expressed COX2. It 
seemed to be expressed at a constant level through stimulation. Lipocortin seemed to be 
constitutively  expressed at a high level in both cells types, and stronger  in cbd-MC. Our 
preliminary PCR and microarray analysis also indicated that HMC-1 cells stimulated with 
C3a and C3a+LPS down-regulated their expression of this cytokine( Results figs 8-12).    
 
 
 
 
Figure 7. Scatter plot showing genes expressed in the HMC-1 after C3a/LPS stimulation. Increased 
expression of genes is illustrated by increased distance to the bisecting line. Red dots represents genes which 
were more than 3 times up-regulated. 
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Figure 8. PCR analysis confirmed the microarray analysis for IL-1β up-regulation following C3a/LPS 
stimulation in HMC-1 cells 
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IL-1β 
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Lipocortin 
IL-1β
IL-5
IL-10
IL-13
C               C            C3a        C3a          C3a/       C3a/      PMA/       PMA/
                                                LPS         LPS         ION          ION 
Figure 9. 
Cytokine mRNA expression by HMC-1 and CBD mast cells after 2 hours stimulation.  
HMC-1/CBD cells (5x105 cells per ml) were grown under conditions as described in Materials and 
Methods. Control cells (C) were harvested after 2 hours. Stimulation was with rhC3a (500ng/ml), rhC3a 
(500ng/ml) + LPS (2µg/ml), or PMA (50ng/ml) + Ionophore (10-6M).
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Figure 10.  Alterations in mRNA expression in HMC-1 cells following stimulation by C3a, LPS/C3a and 
PMA/Ionophore. Columns representing mRNA copies per 104 β-actin based on pixel volume interpretations of 
bands shown in fig. 5 
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Figure 11. Alterations in mRNA expression in cbd-MC cells following stimulation by C3a, LPS/C3a and 
PMA/Ionophore. Columns representing mRNA copies per 104 β-actin based on pixel volume interpretations of 
bands shown in fig.5 
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Figure 12. Mast cells were stimulated with C3a, LPS/C3a and PMA/Ionophore. mRNA expression of a panel 
of cytokines were quantified . mRNA tended to be more highly expressed in cbd-MC. 
Columns expressing mRNA copies per 104 β-actin based on pixel volume interpretations of bands shown in 
figure 9. 
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4.3 HMC-1 express the C3a receptor  
HMC-1 (1,0x106 cells/ml) were stimulated with C3a at different concentrations (100 or 
1000ng/ml) Flow cytometri were executed as described in Materials and Methods. Our 
results indicate that C3a-receptor is expressed on HMC-1 cell surfaces in equal amounts to 
positive controls(C-kit). No internalization of the C3a-receptor could be seen after 20 hours.   
 
HMC-1 and cbd-MC (1x106cells/ml) were further stimulated with IL-4(100ng/ml) and IFN-γ 
(15ng/ml). Flow cytrometric analysis revealed that this did not affect C3a-receptor 
expression, and PCR confirmed that pre-stimulation by IL-4 or IFN-γ did not affect gene 
expression of C3a-reseptor (C3aR) in HMC-1 cells. 
 
Prestim.by IL-4Prestim.by IL-4
Unstimulated
β-actin
 
 
Figure 13.: Pre stimulation with IL-4 in HMC-1 cells did not affect expression of C3a-reseptor (C3aR).  
β-actin confirms equal amounts of cDNA in both samples  
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5. Discussion 
 
5.1 LPS induce TH2 cytokines from mast cells 
Stimulation of cord blood derived mast cells with lipopolysaccharide (LPS) from E. coli or 
peptidoglycan (PGN) from S. Aureus has recently been shown to induce the release of TH2 
associated cytokines: TNF-α, IL-1β, IL-5, IL-10 and IL-13, but not IL-4 from the cells. LPS 
and PGN interact with mast cells through TLR-4 and TLR-2 respectively (5, 10- 13, 50). 
These findings are in agreement with our preliminary studies on gene expression and mRNA 
expression following LPS stimulation. In addition to this, we have shown that cbd-mc 
constitutively express cyclo-oxgenase-2 (COX-2) and that they produce lipocortin. Following 
this project we will focus on a few of these in our continuing studies; IL-1β, IL-5, IL-10, IL-
13, lipocortin, PGD2 and TNF-α.  
 
5.2 C3a induce airway hyper responsiveness 
Asthma is a chronic inflammatory disease of the lung, resulting in airway obstruction. C3a is 
released to the bronchoalveolar lavage fluid (BAL) after allergen challenge in asthmatic 
lungs and the inflammatory infiltrate of eosinophils and neutrophils correlates highly with the 
amount of anaphylatoxin present in BAL (18). A deletion in the C3a receptor gene prevent 
broncho-allergen induced smooth muscle contraction and recruitment of inflammatory cells 
in a murine model of asthma. Human asthmatics generate significant levels of C3a following 
intra-bronchial allergen deposition, but not saline. Thus C3a may be involved in the 
pathogenesis of asthma (16). Both mast cells and eosinophils express the G-protein coupled 
C3a receptor and are thought to be key players in asthmatic responses. Activation of this 
receptor leads to a transient mobilization of intracellular calcium (Ca2+) (15). C3a promotes 
mast cell degranulation, resulting in release of histamine and leukotrienes, both of which can 
induce bronchoconstriction. The importance of non-IgE dependent mast cell activation in 
airway hyper responsiveness is further illustrated in IgE-deficient mice, which can develop 
antigen-induced airway hyper responsiveness (14, 17).  
C3a is found in tissue from asthmatic patients, and regulation of IL-1β, IL-5, IL-13 
and Lipocortin following C3a stimulation would indicate an important role for C3a in the 
development of the disease. In our studies following this report we will investigate the 
relation between C3a stimulation and cytokine expression further. 
 
5.3 Regulation of TH2 associated cytokines 
 
5.3.1 Mast cells regulate IL-1β in response to LPS/C3a stimulation 
IL-1β is up-regulated in both cbd-MC and HMC-1 after stimulation with LPS/C3a. IL-1 is 
(together with TNF-α) considered to be the primary pro-inflammatory cytokine. They induce 
other cells to release a cascade of secondary cytokines amongst which are the chemokines- a 
subfamily of cytokines that attract and activate motile inflammatory cells. It is important 
particularly in the systemic responses of inflammation (e.g. fever), and often works 
synergically with TNF-α. IL-1β induces proliferation of activated B and T cells, PGE2 and 
cytokines from macrophages, neutrophil- and T-cell-adhesion to endothelia, IL-6, IFN-β1 and 
GM-CSF, fever, acute phase proteins and bone resorption by osteoclasts. The induction of 
bone resorption may indicate an important role of mast cells in tissue degeneration following 
periodontal disease. 
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5.3.2 Mast cells are important in recruitment of eosinophils  
Our studies indicate that IL-5 is up-regulated in cbd-MC after stimulation with C3a and 
LPS/C3a. This cytokine is proliferative and chemotaktic on eosinophils, induce B cell 
proliferation, and stimulate IgM and IgA production. IL-4, -5, -6, -10 and -13 are associated 
with TH2 type responses. IL-5 is predominantly involved in the late-phase of allergic 
reactions (51). In situ hybridization studies reveal an increase in the number of cells 
expressing IL-5 mRNA during the allergen induced late-phase reaction (52). These cells 
include eosinophils, mast cells and T cells, all of which produce variable amounts of IL-5 in 
human cutaneous late phase reaction. The strong association between IL-5 levels and asthma 
may be explained by the multiple effects of IL-5 on eosinophils in asthmatic patients. 
Eosinophils cultured in the presence of IL-5 display increased transmigration mediated by 
endothelial ICAM-1, and β2-integrins on the surface of eosinophils (53). Serum levels of IL-5 
during asthmatic exacerbation are significantly elevated as compared with those in remission 
(54). Thus, local IL-5 production may be important in recruiting eosinophils to the 
inflammatory sites. 
 
5.3.3 Mast cells inhibit the TH1 immune response 
The high IL-10 expression in cbd-MC, but not in HMC-1, suggested a maturation dependent 
expression. This indicates that mast cells are able to produce and secrete high levels of this 
cytokine, which is known to down-regulate TH1 responses (26). C3a and LPS did not change 
the level of mRNA IL-10 expression, suggesting that these cells produce it constitutively and 
may be able to excrete it in response to different stimuli. LPS has been reported to up-
regulate IL-10 expression in MC/9 and BMMCs from mice (10) while HMC-1 secrete it 
constitutively (26). IL-10 is known to inhibit IFN-γ secretion from TH1 cells. This underlines 
the fact that mast cells are associated with the TH2 responses.  
 
5.3.4 Bacterial products induce mast cells to produce IL-13 
IL-13 was up-regulated in both HMC-1 and cbd-MC after stimulation with LPS, and grossly 
up-regulated after stimulation with PMA/Ionophore (5, 26) indicating that mast cells respond 
to bacterial inflammation with the production of this cytokine. IL-13 inhibits mononuclear 
phagocyte inflammation, and induce proliferation and differentiation of B cells. IL-13 is 
critical in the development of allergic asthma, although its mode of action is less clear (7). 
 
5.3.5 Mast cells do not regulate TNF-α in response to LPS 
We did not see up-regulation of TNF-α mRNA following stimulation with LPS, but recent 
studies have shown that mast cells secrete this cytokine following such stimulation (5, 26). 
This may indicate that mast cells secrete stored TNF-α when challenged with bacterial toxins. 
TNF-α is involved in tumor cytotoxicity, cachexia, induction of late phase proteins, anti-viral 
and anti-parasitic activity, activation of phagocytic cells, induction of IFN-γ, TNF-α, IL-1, 
GM-CSF and IL-6, and endotoxic shock. It induces adhesion molecules on endothelial cells 
and subsequent transmigration of inflammatory leucocytes (7). Release of pre-fabricated 
TNF-α following LPS stimulation may be one of the body’s responses to bacterial infection. 
 
5.4 Regulation of eicosanoid production 
Both HMC-1 and cbd-MC expressed PGD2-synthetase. Mast cell activation induced new 
synthesis of arachidonic acid metabolites (LTC4, LTB4 and PGD2). Eicosanoids mediate 
bronchoconstriction through interaction with the TP-receptor (main receptor for prostanoid 
TXA2), vasodilatation, venular permeability and inhibition of platelet aggregation through the 
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DP-receptor (main receptor for prostanoid PGD2). They also mediate other early and late 
phase symptoms of asthma and regulate immune cell activation (7, 34, 42, 43). 
Lipocortin seems to be constitutively expressed in both HMC-1 and cbd-MC, but 
stronger in the latter. Lipocortin modulates the inflammatory response through inhibition of 
Phospholipase-A which is an important converting enzyme in the synthesis of eicosanoids 
from arachidonic acid. The eicosanoid production seems to be more complexly regulated 
than first assumed. While stimulation with C3a induced a dramatic up-regulation of 
lipocortin, stimulation with C3a in combination with LPS seemed to inhibit lipocortin 
synthesis. The initial up-regulation following complement activation appeared annulled by 
interaction with E-coli LPS. This suggested a diverse regulation of eicosanoid production in 
mast cells. Whereas, C3a-induced lipocortin up-regulation would result in down-regulated 
eicosanoid production, C3a /LPS induced lipocortin inhibition would have the opposite effect 
and stimulate the production of these mediators. This lipocortin mediated regulation of mast 
cell eicosanoid production could be important in modulating other inflammatory conditions 
such as periodontal disease.  
 
5.5 Mast cells as important regulators of airway remodeling in asthma 
The plasminogen activator (PA) system has an important role in controlling endogenous 
fibrosis and regulating extra cellular matrix (ECM) proteolysis relevant to tissue remodeling. 
The tissue-type PA (tPA) convert plasminogen to plasmin, which enhances proteolytic 
degradation of the ECM via at least three different mechanisms. First, plasmin removes 
glycoprotein from the ECM before matrix metalloprotease (MMP)-dependent degradation of 
collagen. Second, plasmin activates MMPs directly to degrade ECM components. Third, 
plasmin degrades ECM by inhibiting MMP inhibitors. Because of the high concentration of 
plasminogen in virtually all tissues, the production of small amounts of PA can result in high 
local concentrations of plasmin. An important mechanism in the regulation of PA activity is 
inhibition of tPA by three major inhibitors; PAI-1, PAI-2 and PAI-3. Only PAI-1 and PAI-2 
are relevant to lung fibrosis, and PAI-1 is 20- to 100-fold more efficient than PAI-2. Airway 
remodeling in asthma is characterized by subepithelial fibrosis due to extensive deposition of 
ECM. An increase in PAI-1 can block fibrinolysis by MMPs and thereby promote fibrin and 
collagen deposition. The presence of fibrin and collagen is the main feature of airway 
remodeling. HMC-1 was induced to express mRNA for plasminogen activator inhibitor-1 
(PAI-1) after C3a/LPS stimulation. This in agreement with previous reports from Cho et al. 
who found increased release of PAI-1 after PMA/ionophore activation of the HMC-1 cell 
line. This suggest that mast cells can play an important role in airway remodeling of asthma, 
and inhibition of PAI-1 activity can represent a therapeutic approach in the management of 
airway remodeling. (55).  
 
6.  Conclusion 
 
Microarray based screening for changes in mRNA expression followed by PCR-based 
conformation showed that the anaphylatoxin C3a in it self and in combination with 
bacterial LPS induced gene regulatory event. Several pro-inflammatory genes and 
enzymes involved in the production of inflammatory mediators were up-regulated after 
stimulating. The microarray generated more information than we could include in this 
report and thus more work will be needed to clarify the effect C3a stimulation has on 
mast cells. 
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